Raffaello Pellegrino, Roberto Paganelli, Angelo Di Iorio, Stefania Bandinelli, Chiara Mussi, Eleonora Sparvieri, Stefano Volpato, Toshiko Tanaka, Luigi Ferrucci
{"title":"缺乏免疫力会对身体复原力产生负面影响。InCHIANTI 跟踪研究的结果。","authors":"Raffaello Pellegrino, Roberto Paganelli, Angelo Di Iorio, Stefania Bandinelli, Chiara Mussi, Eleonora Sparvieri, Stefano Volpato, Toshiko Tanaka, Luigi Ferrucci","doi":"10.1093/gerona/glae076","DOIUrl":null,"url":null,"abstract":"<p><p>There is consistent evidence that immune response declines with aging, with wide interindividual variability and a still unclear relationship with the development of frailty. To address this question, we assessed the role of immune resilience (capacity to restore immune functions), operationalized as the neutrophil-to-lymphocytes ratio (NL-ratio) and monocytes-to-lymphocytes ratio (ML-ratio), in the pathway that from robust status shifts to pre-frailty and frailty, and finally to death. The InCHIANTI study enrolled representative samples from the registry lists of 2 towns in Tuscany, Italy. Baseline data were collected in 1998, with follow-up visits every 3 years. The 1 453 participants enrolled were assessed and followed for lifestyle, clinical condition, physical performance, clinical, and physiological measures. For the purpose of this analysis, we used only 1 022 subjects aged 65 or older at baseline. Participants in the 3 highest deciles of distribution for NL-ratio (>2.44) were more likely to experience a transition from robust to pre-frail, and to overt frailty status. Moreover, NL-ratio (tenth decile > 3.53) and ML-ratio (tenth decile > 2.02) were both predictors of mortality. These results were independent of chronological age, sex, comorbidities, and chronic low-grade inflammation assessed by high sensitivity C-reactive protein measurement. The 2 leucocytes-derived ratios, NL-ratio and ML-ratio, represent markers of immune resilience and predict changes in physical resilience and mortality. These biomarkers are inexpensive because they are based on data routinely collected in clinical practice and can be used to assess the risk of frailty progression and mortality. Clinical Trials Registration Number: NCT01331512.</p>","PeriodicalId":94243,"journal":{"name":"The journals of gerontology. Series A, Biological sciences and medical sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003532/pdf/","citationCount":"0","resultStr":"{\"title\":\"Lack of Immune Resilience Negatively Affects Physical Resilience: Results From the InCHIANTI Follow-Up Study.\",\"authors\":\"Raffaello Pellegrino, Roberto Paganelli, Angelo Di Iorio, Stefania Bandinelli, Chiara Mussi, Eleonora Sparvieri, Stefano Volpato, Toshiko Tanaka, Luigi Ferrucci\",\"doi\":\"10.1093/gerona/glae076\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There is consistent evidence that immune response declines with aging, with wide interindividual variability and a still unclear relationship with the development of frailty. To address this question, we assessed the role of immune resilience (capacity to restore immune functions), operationalized as the neutrophil-to-lymphocytes ratio (NL-ratio) and monocytes-to-lymphocytes ratio (ML-ratio), in the pathway that from robust status shifts to pre-frailty and frailty, and finally to death. The InCHIANTI study enrolled representative samples from the registry lists of 2 towns in Tuscany, Italy. Baseline data were collected in 1998, with follow-up visits every 3 years. The 1 453 participants enrolled were assessed and followed for lifestyle, clinical condition, physical performance, clinical, and physiological measures. For the purpose of this analysis, we used only 1 022 subjects aged 65 or older at baseline. Participants in the 3 highest deciles of distribution for NL-ratio (>2.44) were more likely to experience a transition from robust to pre-frail, and to overt frailty status. Moreover, NL-ratio (tenth decile > 3.53) and ML-ratio (tenth decile > 2.02) were both predictors of mortality. These results were independent of chronological age, sex, comorbidities, and chronic low-grade inflammation assessed by high sensitivity C-reactive protein measurement. The 2 leucocytes-derived ratios, NL-ratio and ML-ratio, represent markers of immune resilience and predict changes in physical resilience and mortality. These biomarkers are inexpensive because they are based on data routinely collected in clinical practice and can be used to assess the risk of frailty progression and mortality. Clinical Trials Registration Number: NCT01331512.</p>\",\"PeriodicalId\":94243,\"journal\":{\"name\":\"The journals of gerontology. Series A, Biological sciences and medical sciences\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003532/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The journals of gerontology. Series A, Biological sciences and medical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/gerona/glae076\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The journals of gerontology. Series A, Biological sciences and medical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/gerona/glae076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
有一致的证据表明,免疫反应会随着年龄的增长而下降,但个体间的差异很大,而且与虚弱的发展之间的关系仍不明确。为了解决这个问题,我们评估了免疫复原力(恢复免疫功能的能力)在从强健状态转变为衰弱前期和衰弱,最后导致死亡的过程中所起的作用,免疫复原力可以用中性粒细胞与淋巴细胞的比率(NL-ratio)和单核细胞与淋巴细胞的比率(ML-ratio)来表示。InCHIANTI 研究从意大利托斯卡纳两个城镇的登记名单中选取了具有代表性的样本。基线数据于 1998 年收集,每三年进行一次随访。对 1453 名参与者的生活方式、临床状况、身体表现、临床和生理指标进行了评估和跟踪。在本次分析中,我们仅使用了 1022 名基线年龄在 65 岁或以上的受试者。NL-比率(>2.44)分布最高的三个十分位数的受试者更有可能经历从健壮到前期虚弱以及明显虚弱状态的转变。此外,NL 比率(第十分位数大于 3.53)和 ML 比率(第十分位数大于 2.02)都是预测死亡率的因素。这些结果与实际年龄、性别、合并症以及通过高灵敏度 C 反应蛋白测量评估的慢性低度炎症无关。两个白细胞衍生比率,即 NL 比率和 ML 比率,代表了免疫复原力的标志物,可预测身体复原力和死亡率的变化。这些生物标志物基于临床实践中收集的常规数据,成本低廉,可用于评估衰弱进展和死亡风险。
Lack of Immune Resilience Negatively Affects Physical Resilience: Results From the InCHIANTI Follow-Up Study.
There is consistent evidence that immune response declines with aging, with wide interindividual variability and a still unclear relationship with the development of frailty. To address this question, we assessed the role of immune resilience (capacity to restore immune functions), operationalized as the neutrophil-to-lymphocytes ratio (NL-ratio) and monocytes-to-lymphocytes ratio (ML-ratio), in the pathway that from robust status shifts to pre-frailty and frailty, and finally to death. The InCHIANTI study enrolled representative samples from the registry lists of 2 towns in Tuscany, Italy. Baseline data were collected in 1998, with follow-up visits every 3 years. The 1 453 participants enrolled were assessed and followed for lifestyle, clinical condition, physical performance, clinical, and physiological measures. For the purpose of this analysis, we used only 1 022 subjects aged 65 or older at baseline. Participants in the 3 highest deciles of distribution for NL-ratio (>2.44) were more likely to experience a transition from robust to pre-frail, and to overt frailty status. Moreover, NL-ratio (tenth decile > 3.53) and ML-ratio (tenth decile > 2.02) were both predictors of mortality. These results were independent of chronological age, sex, comorbidities, and chronic low-grade inflammation assessed by high sensitivity C-reactive protein measurement. The 2 leucocytes-derived ratios, NL-ratio and ML-ratio, represent markers of immune resilience and predict changes in physical resilience and mortality. These biomarkers are inexpensive because they are based on data routinely collected in clinical practice and can be used to assess the risk of frailty progression and mortality. Clinical Trials Registration Number: NCT01331512.